NCT03775395Unknown3 期
Hepatic Artery Infusion Chemotherapy Plus Lenvatinib vs Hepatic Artery Infusion Chemotherapy Plus Sorafenib for Advanced Hepatocellular Carcinoma
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2018年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
- •Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.
- •Barcelona clinic liver cancer-stage C
- •Eastern Cooperative Oncology Group performance status of 0 to 2
- •with no previous treatment
- •No Cirrhosis or cirrhotic status of Child-Pugh class A only
- •Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
- •The following laboratory parameters:
- •Platelet count ≥ 75,000/μL
- •Hemoglobin ≥ 8.5 g/dL
- •Total bilirubin ≤ 30mmol/L
- •Serum albumin ≥ 30 g/L
- •ASL and AST ≤ 5 x upper limit of normal
- •Serum creatinine ≤ 1.5 x upper limit of normal
- •INR ≤ 1.5 or PT/APTT within normal limits
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Ability to understand the protocol and to agree to and sign a written informed consent document
排除标准
- •Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- •Known history of HIV
- •History of organ allograft
- •Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- •Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- •Evidence of bleeding diathesis.
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- •Known central nervous system tumors including metastatic brain disease
研究组 & 干预措施
HAIC plus Lenvatinib
Experimental
干预措施: Lenvatinib (Drug)
HAIC plus Lenvatinib
Experimental
干预措施: Hepatic arterial infusion chemotherapy (Procedure)
HAIC plus Sorafenib
Active Comparator
干预措施: Sorafenib (Drug)
HAIC plus Sorafenib
Active Comparator
干预措施: Hepatic arterial infusion chemotherapy (Procedure)
结局指标
主要结局
Overall survival
时间窗: Time Frame: 12 months
Overall survival
次要结局
- Time to progression(Time Frame: 12 months)
- Adverse Events([Time Frame: 30 days])
- Progression Free Survival (PFS)(Time Frame: 12 months)
研究者
Shi Ming
Clinical Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
Unknown
3 期
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCCHepatocellular CarcinomaNCT03468231Sun Yat-sen University300
Unknown
2 期
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCCHepatocellular CarcinomaNCT03812770Sun Yat-sen University150
已完成
3 期
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCHepatocellular CarcinomaNCT02774187Sun Yat-sen University247
Unknown
3 期
Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 TrialHepatocellular CarcinomaNCT04687163Sun Yat-sen University400
已完成
不适用
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCarcinoma, HepatocellularLiver NeoplasmsSintilimabPortal Vein Tumor ThrombusNCT04618367Sun Yat-sen University30